ALS (ALQ) H1 2025 earnings summary

Executive summary

• Revenue rose 14% year-over-year to $1,464.2 million, driven by 5.6% organic growth and strong acquisition contributions, despite adverse FX impacts.

• Underlying EBIT increased 2.1% to $250.4 million (8.5% constant currency), reflecting business model resilience and strong Life Sciences growth, especially in Environmental and Food testing.

• Underlying NPAT declined 3.9% to $152.3 million, mainly due to FX headwinds and higher interest costs from acquisitions.

• Cash conversion was robust at 91% of underlying EBITDA, with free cash flow reaching $274.3 million, supporting ongoing investment and dividends.

• Integration of recent acquisitions (Nuvisan, York, Wessling) is progressing well, with Nuvisan transformation ahead of plan.

Financial highlights

• Underlying EBIT margin declined to 17.1% due to acquisition dilution and FX headwinds.

• Interim dividend declared at 18.9c per share (60% payout, 30% franked), totaling $91.6 million.

• Underlying ROCE improved by 66 bps to 19.4%; basic EPS decreased 4.0% to 31.4 cents per share.

• Leverage ratio at 2.3x, at the upper end of the target range, with net debt rising to $1,382.7 million.

• Net interest expense rose to $41 million, reflecting higher debt for acquisitions and increased rates.

Outlook and guidance

• Targeting mid-single digit organic revenue growth for FY25, with Life Sciences expected to outperform commodities and show margin improvement (excluding recent acquisitions); Minerals margins to remain resilient.

• Focus on integrating recent acquisitions and Nuvisan transformation, with capital allocation prioritizing Environmental and Minerals.

• Intention to reduce leverage to mid-point of target range over 12–18 months.

• On track for FY27 targets: $3.3 billion revenue and $600 million EBIT.